Given its multifaceted roles in improving insulin sensitivity, glycemic control, lipid metabolism, body weight regulation, and inflammatory responses, GPR35 has emerged as a promising therapeutic target for metabolic disorders such as type 2 diabetes mellitus (T2DM), obesity, and NAFLD (79). The gene discussed is GPR35; the disease is metabolic dysfunction-associated steatotic liver disease.